Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erosion behaviour of human, bovine and equine dental hard tissues.
Hertel S, Basche S, Schmidt V, Staszyk C, Hannig C, Sterzenbach T, Hannig M. Hertel S, et al. Among authors: hannig c. Sci Rep. 2023 Nov 10;13(1):19617. doi: 10.1038/s41598-023-46759-9. Sci Rep. 2023. PMID: 37949920 Free PMC article.
Sensors for in situ monitoring of oral and dental health parameters in saliva.
Timpel J, Klinghammer S, Riemenschneider L, Ibarlucea B, Cuniberti G, Hannig C, Sterzenbach T. Timpel J, et al. Among authors: hannig c. Clin Oral Investig. 2023 Oct;27(10):5719-5736. doi: 10.1007/s00784-023-05206-9. Epub 2023 Sep 12. Clin Oral Investig. 2023. PMID: 37698630 Free PMC article. Review.
Biofilm modulation and demineralization reduction after treatment with a new toothpaste formulation containing fluoride, casein phosphopeptide-amorphous calcium phosphate, and sodium trimetaphosphate: In situ study.
Gonçalves FMC, de Almeida EMFC, Hannig C, Quinteiro JP, Delbem ACB, Cannon ML, Danelon M. Gonçalves FMC, et al. Among authors: hannig c. Dent Mater. 2024 Dec;40(12):2077-2084. doi: 10.1016/j.dental.2024.09.018. Epub 2024 Oct 17. Dent Mater. 2024. PMID: 39419737 Clinical Trial.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.10.828. Online ahead of print. Ann Oncol. 2024. PMID: 39528049 Free article.
231 results